recent articles
In 2010, results of a phase 3 randomized controlled trial showed that targeted therapy directed against HER2 statistically significantly prolonged overall survival compared with chemotherapy alone in patients with HER2–positive...
© 2023 Tissuepathology.com. All rights reserved. Millennial Consulting. | Web Design by Zealth Digital Marketing